A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

Infantile Spasms Clinical Trial

Official title:

A Double-blind, Placebo-controlled, Dose-ranging Clinical Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of Ganaxolone in Treatment of Patients With Infantile Spasms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00441896
• Other study ID #: 1042-0500
• Status: Completed
• Phase: Phase 2
• Start date: January 2007
• Est. completion date: May 2008

Study information

• Verified date: May 2023
• Source: Marinus Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study consists of cohorts where participants are randomized, in a 2:1 ratio, to 1 of 2 sequences, A and B. In each cohort, Sequence A, comprised of participants, who will receive ascending doses of ganaxolone and ascending doses of placebo. Sequence B, comprised of participants, who will receive ascending doses of placebo and ascending doses of ganaxolone. The dosing level in each subsequent cohort will be based upon experience gained from previous cohorts.

Description:

Male or female, 4 to 24 months of age (inclusive) with a diagnosis of IS with a 24 hour video EEG (vEEG) recording confirming the diagnosis and previously treated with 3 or fewer antiepileptic drugs (AEDs) are eligible for the study. The subject is able to continue treatment with concomitant AEDs (no more than 2; adrenocorticotropic hormone [ACTH], corticosteroids, felbamate, and vigabatrin are not allowed concomitantly). A ketogenic diet is permitted if it can be maintained for the duration of the study.

There will be a total of three weekly 24-hr video EEGs (baseline, end of weeks 1 and 2 of treatment). Dosing titration begins the day after each video EEG during the inpatient stay. All subjects will be receiving ganaxolone the day after the second video EEG.

A Data Monitoring Board (DMB) will determine whether successive cohorts of subjects can be dosed at an increased dose level; up to a maximum of 6 cohorts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: May 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Months to 24 Months

Eligibility

Inclusion Criteria:

• Be diagnosed with IS (regardless of etiology- except for a progressive neurologic illness). Diagnostic Criteria: Seizures consisting of single or repetitive short muscular contractions leading to flexion or extension. Spasms may be characterized as tonic or myoclonic contractions, may occur singly or in clusters, and typically occur bilaterally and symmetrically. The EEG pattern must be consistent with the diagnosis of IS (hypsarrhythmia, modified hypsarrhythmia, multifocal spike wave discharges, etc).

• Have a vEEG recording confirming the diagnosis of IS.

• Have had a magnetic resonance imaging (MRI) performed to determine any possible causes of IS.

• Have been previously treated with 3 or fewer AEDs.

• If being treated with concomitant AEDs

• Current AEDs have been at a constant daily dose for at least 2 weeks; Note:

Subjects with minor dose adjustments may be allowed to enter the study after shorter periods after detailed discussion with the medical monitor.

• Have a stable clinical response/plateau for at least 2 weeks

• Are able to continue treatment with no more than 2 concomitant AEDs (ACTH, corticosteroids, felbamate, and vigabatrin are not allowed concomitantly).

• A ketogenic diet is permitted if it can be maintained for the duration of the study.

• Be a male or female, 4 to 24 months of age (inclusive)

• Have a Parent/Guardian who is properly informed of the nature and risks of the clinical study, who is willing and capable of complying with all clinical study procedures, and has given informed consent in writing prior to entering the clinical study

• Be able to participate for the full term of the clinical study.

Exclusion Criteria:

• Treatment with corticosteroids, ACTH, vigabatrin, felbamate, or any AED not approved by Regulatory Agencies, 2 weeks prior to randomization.

• Treatment with more than two AEDs at baseline.

• Have an active CNS infection, demyelinating disease, degenerative neurological disease, or CNS disease deemed progressive (with the exception of tuberous sclerosis) as evaluated by brain imaging (MRI).

• Have any disease or condition (medical or surgical) at screening that might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product, or would place the subject at increased risk.

• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin greater than four times the upper limit of normal (ULN) or clinical laboratory value deemed clinically significant by the Investigator.

• History of recurrent status epilepticus.

• Have been exposed to any other investigational drug within 30 days prior to randomization.

Related Conditions & MeSH terms

• Infantile Spasms
• Muscle Cramp
• Spasm
• Spasms, Infantile

Intervention

Drug:
• Ganaxolone

Other:
• Placebo

Locations

Country	Name	City	State
United States	Montefiore Medical Center- Albert Einstein College of Medicine	Bronx	New York
United States	University of Chicago Comer Children's Hospital	Chicago	Illinois
United States	Dallas Pediatric Neurology Associates	Dallas	Texas
United States	Texas Children's Hospital	Houston	Texas
United States	Children's Hospital of Los Angeles	Los Angeles	California
United States	Mattel Children's Hospital at UCLA	Los Angeles	California
United States	Le Bonheur Children's Medical Center	Memphis	Tennessee
United States	Miami Children's Hospital, The Brain Institute	Miami	Florida
United States	Children's Hospital of Wisconsin	Milwaukee	Wisconsin
United States	Child Neurology Care Center of Northwest Florida	Pensacola	Florida
United States	Child Neurology Center of Northwest Florida	Pensacola	Florida
United States	Virginia Commonwealth University Health System	Richmond	Virginia
United States	Minnesota Epilepsy Group, P.A.	Saint Paul	Minnesota
United States	Children's Hospital and Regional Medical Center	Seattle	Washington
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Marinus Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Frequency of Spasm Clusters at Day 10	Spasm clusters were determined by a 24-hour video-electroencephalography (vEEG) at Day 10. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the Day 0 assessment before study drug infusion.	Baseline (Day 0) and Day 10
Secondary	Change From Baseline in Frequency of Spasm Clusters at Day 20	Spasm clusters were determined by a 24-hour vEEG at Day 20. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the Day 0 assessment before study drug infusion.	Baseline (Day 0) and Day 20
Secondary	Number of Participants With Absence of Hypsarrhythmia	Absence of hypsarrhythmia was determined by 24-hour vEEG at Day 10 and Day 20.	Day 10 and Day 20
Secondary	Number of Participants With Change in Clinical Status on the Investigator's Global Assessment	The investigators rated the participants' overall clinical status based on 7 clinical factors: seizure frequency, duration, and intensity; adverse experiences; social, intellectual, and motor functioning. Using a 7-point scale ([1] marked improvement, [2] moderate improvement, [3] slight improvement, [4] no change from Baseline, [5] slight worsening, [6] moderate worsening, or [7] marked worsening). Higher score indicated worse symptoms. The investigators assessed the participants' status compared to their condition prior to initiating study medication.	Baseline (Day 0), Day 10 and Day 20
Secondary	Number of Participants With Change in Clinical Status on Caregiver's Global Assessment	Caregiver global assessment of seizure severity and response to treatment rated the participants' based on 7 clinical factors: seizure frequency, duration, and intensity; adverse experiences; social, intellectual, and motor functioning. Using a 7-point scale ([1] marked improvement, [2] moderate improvement, [3] slight improvement, [4] no change from Baseline, [5] slight worsening, [6] moderate worsening, or [7] marked worsening). Higher score indicated worse symptoms. The assessment compared the participants' current status to their condition prior to initiating study medication.	Baseline (Day 0), Day10 and Day 20
Secondary	Number of Participants With Spasm-free Durations	Clinical spasms were determined by vEEG for at least 24 hours at Day 10 and Day 20. The number of participants with spasm-free duration have been presented.	Day 10 and Day 20
Secondary	Number of Participants With Seizure-free Days	Seizure-free days were measured using data obtained from participants' daily dairy. Participants without seizures have been reported.	From Day 8 to Day 10 and From Day 18 to Day 20
Secondary	Number of Responders	A responder is defined as a participant experiencing a greater than equal to (>=) 50 percent (%) decrease in spasm frequency. Test for responders was conducted by vEEG for up to 24 hours at Day 10 and Day 20	Day 10 and Day 20
Secondary	Developmental Assessment Using Denver-II Developmental Test at Day 20	Denver-II Developmental Test measures a child's development in several areas:Personal-Social,Fine Motor-Adaptive,Language,and Gross Motor,from birth to 6 years old.It consists of 125 items that are organized into subscales and scored as pass,fail,or refused.To evaluate a child's progress,test compares their performance to a normative sample of children of same age.For each item,age at which 90% of children in normative sample pass it is determined.Derived score for each subscale is sum of item scores and represents difference between child's chronological age and age at which 90% of children in normative sample pass the items in that subscale.A higher derived score on a subscale indicates better performance on items in that subscale relative to other children of same age who have taken the test.Among subscales,Personal-Social subscale ranges from -16 months to 24 months;others range from - 12 months to 24 months.All subscales have a population mean of 0 and a standard deviation of 3.	At Day 20

External Links

•   information about ganaxolone